I was over the top harsh critiquing Adam Feuerstein's views on Otrexup because upon further review, I find that there is some sprinkling of facts & truths incorporated in the full article.
For instance, oral methotrexate IS the most widely prescribed of the existing options (70% of a total 1.5M RA patients). Injectable methotrexate DOES deliver higher blood levels of the drug over pills. And lastly, IT IS inconvenient for a patient to make office visits to be administered an injection.
Well, the above is at least something that EVERYBODY can agree with!
Now to the disagreement phase. "Rheumatologists and insurers aren't likely to embrace Otrexup"? As expected initial tier3 reimbursement with also expected transition to tier2.. No lack of embrace that I can see! or perhaps the insurers would prefer to foot the bill for biologic therapies instead? "Rheumatologists not likely to embrace Otrexup". Not according to feedback from the top RA authorities and practitioners in the country. Dr. Wotton was "man of the year" at the American College of RA Convention in San Diego fall '13. Ears to the ground! Seasoned sales reps walking in to corporate to apply for a territory on the buzz that building! Combine all that with the highly qualified, highly respected figures in the RA world that represent Antares and one would be remiss not to totally disagree with the AF premise.
"In office injections cheaper"? Really! $548.00 / 4 dose script or $137.00 per vs office visit at ? $150.00???
"The benefits of Otrexup over oral unfounded"? This is just plain silly but exactly why some patients are transitioned off oral to an injected form in the first place. Intramuscular vs no pain in home convenience? That isn't a tough one Adam!
To conclude, AF has written many informative pieces for the Street but I must say , without bias, this had the look and content of something he researched in 10 minutes. Nobody is perfect I suppose!
I have something to say about that article AF wrote that you might find interesting, maybe even compelling. But not tonight, but soon. Interesting comments from that article.
But for now, as far as Adam F, he is paid by "the street" and he tows the line and is a puppet made of the same fabric.
Whatever else you want to say about AF, he was right about this stock so far wasn't he? As was Matasow, as was Cramer, as was WSP. Hard to admit it I know, but all of them nailed it.
I read this piece by AF some months ago and I agree with you that it had a slap-dash, hurriedly done quality that characterizes some of his work. But generally AF is more on the mark than off and any investor with smarts in the biotech sector should pay attention to his writings.
Apologies to the MB for the response to old news, but I felt it necessary to respond to the individual that shall remain nameless!
I find it hard to believe that I actually made an effort to give that guy a heads up looking for nothing in return other than the wishful thinking that he would conduct himself in a more professional manner!
Like trying to turn lead into gold unfortunately!